New Dual-Action drug shows promise in early lung cancer trial

NCT ID NCT04995523

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times

Summary

This study tests a new drug called rilvegostomig (AZD2936) in people with advanced or metastatic non-small cell lung cancer. The drug is designed to boost the immune system's ability to fight cancer by blocking two targets (TIGIT and PD-1). The trial will check for safety, side effects, and whether the drug can shrink tumors. About 212 participants will take part in this early-stage research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

Chicago, Illinois, 60637, United States
Research Site

Rochester, Minnesota, 55905, United States
Research Site

Fairfax, Virginia, 22031, United States
Research Site

Melbourne, 3000, Australia
Research Site

Anderlecht, 1070, Belgium
Research Site

Leuven, 3000, Belgium
Research Site

Florianópolis, 88034-000, Brazil
Research Site

Natal, 59075-740, Brazil
Research Site

Porto Alegre, 90035903, Brazil
Research Site

Rio de Janeiro, 20231-050, Brazil
Research Site

São Paulo, 01246-000, Brazil
Research Site

Chengdu, 610041, China
Research Site

Chongqing, 400030, China
Research Site

Copenhagen, 2100, Denmark
Research Site

Dijon, 21079, France
Research Site

Toulouse, 31059, France
Research Site

Tbilisi, 0112, Georgia
Research Site

Kashiwa, 227-8577, Japan
Research Site

Niigata, 951-8566, Japan
Research Site

Sendai, 981-0914, Japan
Research Site

Tokyo, 104-0045, Japan
Research Site

Kuala Lumpur, 59100, Malaysia
Research Site

Kuching, 93586, Malaysia
Research Site

Chisinau, MD-2025, Moldova
Research Site

Groningen, 9713 GZ, Netherlands
Research Site

Leiden, 2333 ZA, Netherlands
Research Site

Utrecht, 3584 CX, Netherlands
Research Site

Seoul, 03082, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Barcelona, 08035, Spain
Research Site

Madrid, 28027, Spain
Research Site

Madrid, 28041, Spain
Research Site

Taichung, 40201, Taiwan
Research Site

Taichung, Taiwan
Research Site

Tainan, 70403, Taiwan
Research Site

Taipei, 110, Taiwan
Research Site

Bangkok, 10700, Thailand
Research Site

Chanthaburi, 22000, Thailand
Research Site

Muang, 50200, Thailand

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

rilvegostomig (AZD2936), a bispecific antibody that targets two immune checkpoints (TIGIT and PD-1)

What this could lead to

If successful, this could provide a new treatment option for advanced lung cancer by helping the immune system attack cancer cells more effectively.

What could go wrong

This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. The drug may cause immune-related side effects or not work for all patients.

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CARCINOMA NON-SMALL CELL LUNG CARCINOMA